AB Science SA is using Masitinib in phase III trials for patients with mild to moderate AD (NCT01872598), a wide variety of tumours such as gastrointestinal stromal tumours (NCT01694277), ALS (NCT02588677; NCT03127267) and multiple sclerosis (NCT01433497), based on the activity of the compound over CSF1R or c-kit, depending on the specific disease mechanism. This evidence concerns the gene CSF1R and neoplasm.